AI Article Synopsis
- - The study explored the use of cationically modified solid lipid nanoparticles (SLN) as carriers for plasmid DNA (pDNA) to be delivered through inhalation.
- - Researchers created pDNA-loaded SLN using specific lipids and chitosan, resulting in nanoparticles around 200 nm in size, which maintained plasmid stability and showed low toxicity in pulmonary cells.
- - The findings suggest that microencapsulated SLN are a safe and effective method for delivering genes to the lungs, making them suitable for pulmonary gene therapy.
Article Abstract
Aim: Cationically modified solid lipid nanoparticles (SLN) were investigated as plasmid DNA (pDNA) carriers and transfection agents for the pulmonary route.
Materials & Methods: pDNA-loaded SLN were produced using glyceryl dibehenate or tristearate as matrix lipids and chitosan as surface charge modifier, and encapsulated by spray-drying in mannitol and trehalose microspheres.
Results: Nanoparticles of 200 nm, and zeta potential around +15 mV were produced. Electrophorectic analysis confirmed plasmid stability and integrity. The pDNA-loaded SLN were able to transfect the Calu-3 and A549 pulmonary cell lines, while showing low cytotoxicity. Microencapsulation of SLN yielded dry powders suitable for inhalation that protected pDNA from degradation.
Conclusion: Microencapsulated SLN are a promising safe and effective carrier system for pulmonary gene delivery following pulmonary administration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/nnm-2018-0270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!